Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

FDA Distributes $23M Grant for Rare Disease R&D Initiatives

By Ryan Bushey | October 19, 2016

A variety of rare disease research programs received a financial boost on Monday.

The Food and Drug Administration (FDA) announced it would distribute a grant worth more than $23 million through the Orphan Products Clinical Trials Grants program. The funding will be allocated to 21 finalists, a mix of academic institutions and private companies, over a four year period to help with clinical development for their respective rare disease research initiatives.

“We are proud of our 30-year track record of fostering and encouraging the development of safe and effective therapies for rare diseases through our clinical trials grant program,” said Gayatri Rao, director of the FDA’s Office of Orphan Product Development, within the Office of Special Medical Programs in a statement.

“The grants awarded this year will support much-needed research in 21 different rare diseases, many of which have little, or no, available treatment options,” continued Dr. Rao.

Some of the beneficiaries include biotech firms Chemigen and Scioderm, reported FiercePharma.  The former will use about a quarter of a million dollars to launch a Phase 1 study of its Amytrophic Lateral Sclerosis candidate whereas the former plans on using an estimated half a million dollars to advance a late-stage study of its rare skin disorder therapy targeting epidermolysis bullosa.

Other finalists like Johns Hopkins University will be granted $750,000 over three years for research on a cystic fibrosis treatment. The University of Alabama at Birmingham will receive a similar amount for a phase 1 study focusing on an early-stage combination therapy targeting pediatric brain tumors.

This FDA program has provided over $370 million in funding for more than 590 new clinical studies since it was formed in 1983.

You can see who else was on this final list here.


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE